Both the FGF2-neutralizing antibody and PD-166866 inhibited the expression levels of p-FGFR1 and FAPα in HSCs (Figure 6C and Supplemental Figure 10C), suppressed the recruitment of Gr-1+ MDSCs (Figure 6D and Supplemental Figure 10D), decreased the expression of vimentin, and increased the expression of E-cadherin in tumor cells (Supplemental Figure 10E). This evidence concerns the gene FGF2 and neoplasm.